Cortexyme, Inc. (NASDAQ:CRTX - Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.12 and traded as high as $1.95. Cortexyme shares last traded at $1.95, with a volume of 118,865 shares traded.
Cortexyme Stock Up 2.1 %
The company's 50-day simple moving average is $1.84 and its 200-day simple moving average is $1.13. The stock has a market cap of $60.00 million, a price-to-earnings ratio of -0.67 and a beta of 1.40.
About Cortexyme
(
Get Free Report)
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Read More
Before you consider Cortexyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cortexyme wasn't on the list.
While Cortexyme currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
